JP2025503214A5 - - Google Patents
Info
- Publication number
- JP2025503214A5 JP2025503214A5 JP2024544709A JP2024544709A JP2025503214A5 JP 2025503214 A5 JP2025503214 A5 JP 2025503214A5 JP 2024544709 A JP2024544709 A JP 2024544709A JP 2024544709 A JP2024544709 A JP 2024544709A JP 2025503214 A5 JP2025503214 A5 JP 2025503214A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- drug conjugate
- pharmaceutically acceptable
- isomer
- her3 antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210107800 | 2022-01-28 | ||
| CN202210107800.8 | 2022-01-28 | ||
| CN202310015113.8 | 2023-01-05 | ||
| CN202310015113 | 2023-01-05 | ||
| PCT/CN2023/073130 WO2023143365A1 (zh) | 2022-01-28 | 2023-01-19 | Her3抗体药物偶联物及其用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025503214A JP2025503214A (ja) | 2025-01-30 |
| JP2025503214A5 true JP2025503214A5 (cg-RX-API-DMAC10.html) | 2026-01-26 |
Family
ID=87470787
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024544709A Pending JP2025503214A (ja) | 2022-01-28 | 2023-01-19 | Ｈｅｒ３抗体－薬物結合体及びその使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250295802A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4470570A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025503214A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240157659A (cg-RX-API-DMAC10.html) |
| CN (1) | CN118434453A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023213783A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL314567A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2024009159A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202341984A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023143365A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250079213A (ko) | 2022-10-09 | 2025-06-04 | 라노바 메디신즈 리미티드 | 화합물, 조성물 및 방법 |
| IL320634A (en) * | 2022-11-04 | 2025-07-01 | Alx Oncology Inc | EXATECAN derivatives and antibody-drug conjugates |
| EP4692091A1 (en) * | 2023-04-07 | 2026-02-11 | Changchun Genescience Pharmaceutical Co., Ltd. | Camptothecin derivative, and pharmaceutical composition, preparation method therefor and use thereof |
| JPWO2024248123A1 (cg-RX-API-DMAC10.html) | 2023-06-02 | 2024-12-05 | ||
| CN120958033B (zh) * | 2023-08-04 | 2026-03-31 | 映恩生物制药（苏州）有限公司 | 抗体药物偶联物的识别抗体及其应用 |
| WO2026145527A1 (zh) * | 2024-12-30 | 2026-07-09 | 映恩生物制药（苏州）有限公司 | 抗her3抗体药物偶联物的用途和使用方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AR056857A1 (es) | 2005-12-30 | 2007-10-24 | U3 Pharma Ag | Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos |
| TWI871999B (zh) * | 2014-04-10 | 2025-02-01 | 日商第一三共股份有限公司 | 抗her3抗體-藥物結合物 |
| WO2020059772A1 (ja) * | 2018-09-20 | 2020-03-26 | 第一三共株式会社 | 抗ｈｅｒ３抗体－薬物コンジュゲート投与によるｈｅｒ３変異がんの治療 |
| UA130338C2 (uk) * | 2018-09-26 | 2026-01-28 | Джянгсу Хенгруй Медісін Ко., Лтд. | Кон'югат ліганд-лікарський засіб аналога ексатекану, спосіб його отримання та його застосування |
| DK4516357T3 (da) * | 2020-09-30 | 2026-04-27 | Duality Biologics Suzhou Co Ltd | Antitumorforbindelse, fremgangsmåde til fremstilling deraf og anvendelse deraf |
| EP4355787A4 (en) * | 2021-06-15 | 2025-04-30 | Beijing Sinotau Bio-Pharmaceuticals Technology Co., Ltd. | Anti-her3 antibody, antibody drug conjugate containing the same, and use thereof |
-
2023
- 2023-01-19 EP EP23746246.0A patent/EP4470570A1/en active Pending
- 2023-01-19 US US18/833,846 patent/US20250295802A1/en active Pending
- 2023-01-19 TW TW112102804A patent/TW202341984A/zh unknown
- 2023-01-19 IL IL314567A patent/IL314567A/en unknown
- 2023-01-19 WO PCT/CN2023/073130 patent/WO2023143365A1/zh not_active Ceased
- 2023-01-19 KR KR1020247027679A patent/KR20240157659A/ko active Pending
- 2023-01-19 MX MX2024009159A patent/MX2024009159A/es unknown
- 2023-01-19 JP JP2024544709A patent/JP2025503214A/ja active Pending
- 2023-01-19 CN CN202380013747.8A patent/CN118434453A/zh active Pending
- 2023-01-19 AU AU2023213783A patent/AU2023213783A1/en active Pending